The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...

Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced ...

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, announced an option to license agreement to develop SIM0500, ...

AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd, have entered into an option-to-license agreement ...

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in ...

SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an ...

NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to ...

trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a ...

SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform.